| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd3996e920e03d544a87b47c7bbd3029 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-061
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-605 |
| filingDate |
2020-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b531251e6cba5d3a5d6b6d8544bbcac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdcd820214eee3925ced6b48b13d64e3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3df9f3010532b137957bb17372739e5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf2f95d7b329f4e0d99046dee5f170c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05ff60162ae9775a635fb34e777450e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7688882e5f42f34f021eb35d865bc710 |
| publicationDate |
2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020161664-A9 |
| titleOfInvention |
Glucagon-like peptide-1 (glp-1) agonist analog, process of preparation and uses thereof |
| abstract |
The present disclosure relates to an analog of glucagon-like peptide-1 (glp-1)receptor agonist. The present disclosure provides analogs of glucagon-like peptide-1 (glp-1) receptor agonist wherein, the amino acid at position 2 of the 5 glucagon-like peptide-1 (glp-1)receptor agonist is replaced with D-Alanine. The analogs of glucagon-like peptide-1 (glp-1) have one or more properties of prolonged half-life, better pharmacokinetic profile, retained biological activity, and being advantageous for relieving the patient's burden by reducing the dosing frequency and dose. The present disclosure further provides processes for 10 preparing synthetic glucagon-like peptide-1 (glp-1) analogs. |
| priorityDate |
2019-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |